A Life Science Company

New Single-dose Treatment for Canine Otitis Externa Launches in Canada

Claro® provides veterinarians with an effective first-line therapy that eliminates the need for in-home application by pet owners Read more

Bayer Inc. investing $500,000 in STEM education for Canadian youth through Let’s Talk Science

Read more

Bayer’s darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival by 22 months, with a favourable safety profile compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer

Darolutamide significantly improved median metastasis-free survival (MFS) by 22 months (40.4 months with darolutamide plus androgen deprivation therapy (ADT) versus 18.4 months for placebo plus ADT / Positive trend in overall survival with a 29% reduction in risk of death at interim analysis (P=0.045) / Incidence of treatment-emergent adverse events was similar between darolutamide plus ADT and placebo plus ADT/ Health-related quality of life was maintained/ First results from the Phase III ARAMIS trial with the androgen receptor antagonist darolutamide were presented in an oral presentation at American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2019 and simultaneously published in The New England Journal of Medicine Read more

Bayer increases sales and earnings – leader in agriculture after acquisition

Read more